Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price target was ...

Retailers' investments have ranged from strategic pivots for existing clinics to multibillion-dollar acquisitions of primary ...

The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.

The FDA announced a proposal to remove oral phenylephrine – a common ingredient in many popular over-the-counter ...

An extensive review determined that the ingredient, oral phenylephrine, doesn’t actually relieve nasal congestion.

TD Cowen analyst Charles Rhyee maintained a Buy rating on CVS Health (CVS – Research Report) today and set a price target of $85.00. The ...

But today, according to the Federal Trade Commission, the six largest PBMs — CVS Caremark, Express Scripts ... leaving patients to pay more at the pharmacy counter. The abusive practices of PBMs take ...

GoodRx and pharmacy benefit managers CVS Caremark, Express Scripts, MedImpact and Navitus Health Solutions are facing class-action lawsuits accusing them of colluding to super press reimbursements to ...

CVS Health (NYSE:CVS) offers a wide range of health solutions in the U.S., including health insurance products and services, ...

CVS Health fell short on third-quarter profit, but it posted strong sales and the health care giant shook up leadership under ...

Before we dive into the specifics of this recent uptick, it’s worth looking at how CVS Health has been performing on a year-to-date (YTD) basis compared to the broader market. As of the most recent ...